Specialty Pharma Intermediates (Chiral)
$0.45 bnAnnual import
30%Indian capability
4,250Supplier concentration (HHI)
₹2,000 crTo localise
Why India imports it. China dominates specialty pharma intermediates; Indian Archimica and Divi's growing.
Why it matters. API localisation needs intermediate upstream.
Can India localise it? Yes - 3-5 years.
Where it comes from. China (60%), Germany (25%), Switzerland (10%).
Scorecard
The ten indices
CMDI 67.5Dependency
LPI 53.5Localisation potential
IAI 61.25Investment attractiveness
SRI 63.5Supply risk
SCI 51.5Supply-chain complexity
TRI 40.25Technology readiness
IMI 67Industrial multiplier
NSRI 57.25National-security relevance
EPI 62Export potential
ICGI 59.25Capability gap
Who makes it
Manufacturers
In India
Divi's LaboratoriesArchimica
Global leaders
BasfLanxessPorton
Intelligence
Related signals
- India Now Has a Structured Map of Where It Stays Import-Dependent
- India's Deepest Chokepoints: EUV Photoresist, Leading-Edge Logic and Aero-Engines
- Where Dependency Meets Feasibility: SiC Power and Display-Driver ICs Are the Build-Now Surfaces
- High-Purity Minerals Enter the Semiconductor Feedstock Chain
Sources
Primary references
Confidence: Reasoned estimate. Reasoned estimate. Part of Techadyant Labs' Critical Manufacturing Dependencies (Edition I).